CA2084519A1 - Method for treating alcoholism with nalmefene - Google Patents

Method for treating alcoholism with nalmefene

Info

Publication number
CA2084519A1
CA2084519A1 CA 2084519 CA2084519A CA2084519A1 CA 2084519 A1 CA2084519 A1 CA 2084519A1 CA 2084519 CA2084519 CA 2084519 CA 2084519 A CA2084519 A CA 2084519A CA 2084519 A1 CA2084519 A1 CA 2084519A1
Authority
CA
Canada
Prior art keywords
nalmefene
treating alcoholism
alcoholism
treating
alcoholdrinking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2084519
Other languages
French (fr)
Other versions
CA2084519C (en
Inventor
John D. Sinclair
Harry Scheinin
Risto Lammintausta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Contral Clinics Oy
Original Assignee
John D. Sinclair
Harry Scheinin
Risto Lammintausta
Orion-Yhtyma Oy
Alko Ltd.
Alko Group Ltd.
Contral Clinics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John D. Sinclair, Harry Scheinin, Risto Lammintausta, Orion-Yhtyma Oy, Alko Ltd., Alko Group Ltd., Contral Clinics Oy filed Critical John D. Sinclair
Publication of CA2084519A1 publication Critical patent/CA2084519A1/en
Application granted granted Critical
Publication of CA2084519C publication Critical patent/CA2084519C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse

Abstract

A method for treating alcoholism. The alcoholdrinking response of alcoholics is extinguished by having them drink alcoholic beverages while nalmefene, an opiate antagonist, blocks the positive reinforcement effect of ethanol in the brain.
CA002084519A 1990-06-04 1991-05-10 Method for treating alcoholism with nalmefene Expired - Lifetime CA2084519C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US532,424 1990-06-04
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene

Publications (2)

Publication Number Publication Date
CA2084519A1 true CA2084519A1 (en) 1991-12-05
CA2084519C CA2084519C (en) 1999-02-09

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002084519A Expired - Lifetime CA2084519C (en) 1990-06-04 1991-05-10 Method for treating alcoholism with nalmefene

Country Status (19)

Country Link
US (1) US5086058A (en)
EP (1) EP0531415B1 (en)
JP (1) JP3059213B2 (en)
AT (1) ATE145329T1 (en)
AU (1) AU642748B2 (en)
CA (1) CA2084519C (en)
DE (1) DE69123247T2 (en)
DK (1) DK0531415T3 (en)
ES (1) ES2097209T3 (en)
FI (1) FI925513A (en)
GR (1) GR3022289T3 (en)
HU (1) HU210637B (en)
IE (1) IE77333B1 (en)
LT (1) LT3893B (en)
LV (1) LV10190B (en)
NZ (1) NZ238391A (en)
RU (1) RU2090190C1 (en)
WO (1) WO1991018605A1 (en)
ZA (1) ZA914185B (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
WO1999032119A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
UA53774C2 (en) * 1997-12-22 2003-02-17 Еро-Селтік, С.А. Method of reducing abuse potential of an oral dosage form of opioid analgesic
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CA2392510A1 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
HU229705B1 (en) * 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
ATE493130T1 (en) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc MEDICINAL FORM CONTAINING OPIOID AGAINST ABUSE
EP1411352B1 (en) * 2001-07-13 2012-01-11 ARKRAY, Inc. Analysing instrument and lancet-integrated attachment for concentration measuring device
DE60230632D1 (en) * 2001-07-18 2009-02-12 Euro Celtique Sa PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE
WO2003013433A2 (en) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
ATE431738T1 (en) 2001-08-06 2009-06-15 Euro Celtique Sa OPIOID AGONIST FORMULATIONS WITH RELEASABLE AND SEQUESTRED ANTAGONIST
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
JP2005508888A (en) * 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション How to treat alcoholism or alcoholism
EP2243471A1 (en) 2002-04-05 2010-10-27 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
DK1551372T3 (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
NZ542548A (en) 2003-03-31 2009-04-30 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050038062A1 (en) * 2003-04-14 2005-02-17 Burns Lindsay H. Methods and materials for the treatment of pain comprising opioid antagonists
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
CN101677963B (en) 2006-06-19 2012-05-30 奥尔制药公司 Pharmaceutical compositions
CA2666846C (en) 2006-10-20 2018-04-10 Cpd, Llc Method of restoring the incretin effect
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
DK2291380T3 (en) * 2008-04-24 2011-12-05 Janssen Pharmaceutica Nv Nalmefene prodrugs
KR101598138B1 (en) * 2008-04-24 2016-02-29 얀센 파마슈티카 엔.브이. Nalmefene di-ester prodrugs
BRPI0910780A2 (en) * 2008-07-07 2016-08-09 Euro Celtique Sa use of opioid antagonists for the treatment of urinary retention
DK2405915T3 (en) 2009-03-10 2019-02-11 Euro Celtique Sa PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
KR20180037074A (en) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US20170042887A1 (en) * 2014-04-22 2017-02-16 Otsuka Pharmaceutical. Co., Ltd. Combination of Brexpiprazole and Nalmefene and Use Thereof for Treating Substance-Related Disorders
ES2787223T3 (en) 2014-11-07 2020-10-15 Univ Minnesota Salts and compositions useful for treating diseases
BR112018071705A2 (en) * 2016-04-22 2019-02-19 Taiwanj Pharmaceuticals Co., Ltd. prophylaxis method or treatment of nafld, nash or ash, use of a compound of formula (i), and compound of formula (i)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Also Published As

Publication number Publication date
DE69123247D1 (en) 1997-01-02
HUT65523A (en) 1994-06-28
ATE145329T1 (en) 1996-12-15
DK0531415T3 (en) 1996-12-09
JP3059213B2 (en) 2000-07-04
EP0531415A1 (en) 1993-03-17
AU7974091A (en) 1991-12-31
RU2090190C1 (en) 1997-09-20
IE77333B1 (en) 1997-12-03
ZA914185B (en) 1992-07-29
FI925513A0 (en) 1992-12-04
CA2084519C (en) 1999-02-09
US5086058A (en) 1992-02-04
IE911888A1 (en) 1991-12-04
ES2097209T3 (en) 1997-04-01
AU642748B2 (en) 1993-10-28
FI925513A (en) 1992-12-04
DE69123247T2 (en) 1998-01-15
LV10190B (en) 1995-06-20
JPH06506665A (en) 1994-07-28
LT3893B (en) 1996-04-25
LTIP1486A (en) 1995-09-25
EP0531415B1 (en) 1996-11-20
HU9203835D0 (en) 1993-03-29
HU210637B (en) 1995-06-28
GR3022289T3 (en) 1997-04-30
LV10190A (en) 1994-10-20
NZ238391A (en) 1997-06-24
WO1991018605A1 (en) 1991-12-12

Similar Documents

Publication Publication Date Title
CA2084519A1 (en) Method for treating alcoholism with nalmefene
RU92016403A (en) METHOD OF TREATMENT OF ALCOHOLISM NALMEPHEN
MXPA99001239A (en) Improved process for the production of alcoholic beverages using maltseed.
AU7201194A (en) Spiro-substituted azacycles as neurokinin antagonists
AU5520298A (en) Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
EP0613912A3 (en) Process for producing ethylene-propylene block copolymer.
AU3838097A (en) Process for the production of alcholic coffee drinks
ZA9472B (en) Process for producing low molecular-weight poly-1-olefins.
AU5102490A (en) Process of treating alcoholic beverages by vapor-arbitrated pervaporisation
CA2119651A1 (en) Immunoassay for identifying alcoholics and monitoring alcohol consumption
AU7275994A (en) Process for producing emulsion fuel
MD188B2 (en) Process for producing the extract for alcoholic beverages
GR1001893B (en) Process for manufacturing decorative sheeting for nativity scenes, shop windows, fish tank bottoms and other uses.
AU1129295A (en) Certain tricyclic substituted diazabicyclo{3.2.1} octane derivatives
EP0652234A3 (en) Reduced fouling in process for production of EP.
HUT64765A (en) Method for producing oxa-bicyclo[2.2.1] heptane-2,3-dimethanol-derivatives
AU586626B2 (en) Process for the production of low-calorie alcoholic beverages
AU2767192A (en) Process for producing chloroisocyanurates with hypochlorous acid
AU4328093A (en) Method for producing a conglomerate with low water demand
AU6887094A (en) Process for manufacturing fermented beverages
AU6045394A (en) Process for producing intermediate for 13,14-didehydroprostaglandin e
HU204887B (en) Process for producing drinks, particularly parfumed cocktails from alcoholic or alcohol-free drinks
AU4327993A (en) Method for producing a decorative conglomerate with low water demand
HUT66951A (en) Process for producing mannit by stereoselective hydrogenation on glas-supported copper-catalyst with the controlled pore volume
LV10483B (en) Process for producing sparkling wines

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry